Table 1.
Clinical characteristics and laboratory data of analyzed subjects classified by OGTT (N = 512)
| Overall (n = 512) | NGT (n = 220, 42.9%) | IGT (n = 191, 37.3%) | DM (n = 101, 19.7%) | p-value | |
|---|---|---|---|---|---|
| Female (%) | 60.5% | 58.6% | 58.6% | 68.3% | 0.205 |
| Age (years) | 50.3 ± 12.7 | 48.4 ± 12.8 | 50.3 ± 11.4 | 54.3 ± 14 | 0.001 |
| BMI (kg/m2) | 26.5 ± 4.6 | 26.1 ± 4.7 | 26.7 ± 4.5 | 27.0 ± 4.6 | 0.189 |
| Systolic BP (mmHg) | 126 ± 16 | 124 ± 16 | 126 ± 15 | 131 ± 15 | < 0.001 |
| Diastolic BP(mmHg) | 74 ± 11 | 74 ± 11 | 75 ± 11 | 74 ± 11 | 0.578 |
| Fasting plasma glucose | 103 ± 12 | 98 ± 9 | 103 ± 11 | 112 ± 15 | < 0.001 |
| 2-h plasma glucose | 155 ± 51 | 111 ± 19 | 163 ± 17 | 236 ± 29 | < 0.001 |
| Hypertension | 31.8% | 27.7% | 32.5% | 39.6% | 0.103 |
| History of smoking | 10.4% | 11.0% | 11.1% | 7.9% | 0.422 |
| Statin usage | 37% | 34% | 40% | 40% | 0.370 |
| History of CVD | 2.3% | 1.8% | 2.1% | 4.0% | 0.339 |
| Family History of DM | 60.2% | 57.7% | 59.7% | 66.3% | 0.339 |
| HbA1c (%NGSP) | 5.8 ± 0.5 | 5.6 ± 0.4 | 5.8 ± 0.5 | 6.1 ± 0.5 | < 0.001 |
| Total Cholesterol (mg/dL) | 199 ± 39 | 199 ± 39 | 198 ± 40 | 200 ± 36 | 0.949 |
| Fasting Triglyceride (mg/dL) | 138 ± 83 | 128 ± 75 | 149 ± 102 | 138 ± 48 | 0.081 |
| HDL (mg/dL) | 53 ± 15 | 55 ± 16 | 51 ± 15 | 52 ± 12 | 0.048 |
| LDL (mg/dL) | 125 ± 37 | 125 ± 38 | 126 ± 39 | 124 ± 30 | 0.883 |
| VFAa (cm2) | 130 ± 39 | 129 ± 41 | 131 ± 39 | 129 ± 34 | 0.963 |
| WC (cm) | 94.5 ± 13 | 94.1 ± 13 | 94.9 ± 13 | 94.7 ± 12 | 0.909 |
| Thai DM risk score (points) | 9 ± 4 | 8 ± 4 | 9 ± 3 | 10 ± 3 | 0.003 |
| Thai CV risk scoreb (points) | 4 (1–10) | 3 (1–7) | 4 (1–9) | 10 (2–19) | < 0.001 |
a Available in 268/512 overall subjects (107/220 in NGT, 112/191 in IGT, 49/101 in DM)
b Displayed as median (IQR)